Request for Comments on Discretion To Institute Trials Before the Patent Trial and Appeal Board, 66502-66506 [2020-22946]
Download as PDF
66502
Federal Register / Vol. 85, No. 203 / Tuesday, October 20, 2020 / Proposed Rules
A rule has implications for federalism
under Executive Order 13132,
(Federalism), if it has a substantial
direct effect on the States, on the
relationship between the national
government and the States, or on the
distribution of power and
responsibilities among the various
levels of government. We have analyzed
this proposed rule under that Order and
have determined that it is consistent
with the fundamental federalism
principles and preemption requirements
described in Executive Order 13132.
Also, this proposed rule does not have
tribal implications under Executive
Order 13175, (Consultation and
Coordination with Indian Tribal
Governments), because it would not
have a substantial direct effect on one or
more Indian tribes, on the relationship
between the Federal Government and
Indian tribes, or on the distribution of
power and responsibilities between the
Federal Government and Indian tribes.
If you believe this proposed rule has
implications for federalism or Indian
tribes, please contact the person listed
in the FOR FURTHER INFORMATION
CONTACT section.
E. Unfunded Mandates Reform Act
The Unfunded Mandates Reform Act
of 1995 (2 U.S.C. 1531–1538) requires
Federal agencies to assess the effects of
their discretionary regulatory actions. In
particular, the Act addresses actions
that may result in the expenditure by a
State, local, or tribal government, in the
aggregate, or by the private sector of
$100,000,000 (adjusted for inflation) or
more in any one year. Though this
proposed rule will not result in such an
expenditure, we do discuss the effects of
this proposed rule elsewhere in this
preamble.
F. Environment
We have analyzed this proposed rule
under Department of Homeland
Security Management Directive 023–01,
Rev.1, associated implementing
instructions, and Environmental
Planning Policy COMDTINST 5090.1
(series), which guide the Coast Guard in
complying with the National
Environmental Policy Act of 1969
(NEPA)(42 U.S.C. 4321–4370f). The
Coast Guard has determined that this
action is one of a category of actions
which do not individually or
cumulatively have a significant effect on
the human environment. This proposed
rule simply promulgates the operating
regulations or procedures for
drawbridges. Normally such actions are
categorically excluded from further
review, under paragraph L49, of Chapter
3, Table 3–1 of the U.S. Coast Guard
VerDate Sep<11>2014
16:48 Oct 19, 2020
Jkt 253001
Environmental Planning
Implementation Procedures.
Neither a Record of Environmental
Consideration nor a Memorandum for
the Record are required for this rule. We
seek any comments or information that
may lead to the discovery of a
significant environmental impact from
this proposed rule.
G. Protest Activities
The Coast Guard respects the First
Amendment rights of protesters.
Protesters are asked to contact the
person listed in the FOR FURTHER
INFORMATION CONTACT section to
coordinate protest activities so that your
message can be received without
jeopardizing the safety or security of
people, places or vessels.
V. Public Participation and Request for
Comments
We view public participation as
essential to effective rulemaking, and
will consider all comments and material
received during the comment period.
Your comment can help shape the
outcome of this rulemaking. If you
submit a comment, please include the
docket number for this rulemaking,
indicate the specific section of this
document to which each comment
applies, and provide a reason for each
suggestion or recommendation.
We encourage you to submit
comments through the Federal
eRulemaking Portal at https://
www.regulations.gov. If your material
cannot be submitted using https://
www.regulations.gov, contact the person
in the FOR FURTHER INFORMATION
CONTACT section of this document for
alternate instructions.
We accept anonymous comments. All
comments received will be posted
without change to https://
www.regulations.gov and will include
any personal information you have
provided. For more about privacy and
submissions in response to this
document, see DHS’s eRulemaking
System of Records notice (85 FR 14226,
March 11, 2020).
Documents mentioned in this NPRM
as being available in this docket and all
public comments, will be in our online
docket at https://www.regulations.gov
and can be viewed by following that
website’s instructions. Additionally, if
you go to the online docket and sign up
for email alerts, you will be notified
when comments are posted or a final
rule is published.
List of Subjects in 33 CFR Part 117
PO 00000
Bridges.
Frm 00012
Fmt 4702
Sfmt 4702
For the reasons discussed in the
preamble, the Coast Guard proposes to
amend 33 CFR part 117 as follows:
PART 117—DRAWBRIDGE
OPERATION REGULATIONS
1. The authority citation for part 117
continues to read as follows:
■
Authority: 33 U.S.C. 499; 33 CFR 1.05–1;
DHS Delegation No. 0170.1.
■
2. Revise § 117.297 to read as follows:
§ 117.297
Little Manatee River.
The draw for the CSX Railroad Bridge,
mile 2.4 near Ruskin FL, shall operate
as follows:
(a) The bridge is normally maintained
in the closed position.
(b) The bridge is not tendered locally,
but will be monitored and operated by
a remote bridge tender. The draw must
open if at least three hours advance
notice is requested via marine radio
channel 9 VHF or telephone (813) 677–
3974.
(c) Marine radio communication shall
be maintained, by the remote bridge
tender, with mariners near the bridge for
the safety of navigation. Visual
monitoring of the waterway shall be
maintained with the use of cameras.
Detection sensors shall be installed for
the detection of vessels approaching the
spans.
(d) The bridge shall not be operated
from the remote location in the
following events: Failure or obstruction
of the detection sensors, cameras or
marine radio communications. In these
situations, a bridge tender must be onsite and locally operate the bridge.
Dated: October 7, 2020.
Eric C. Jones,
Rear Admiral, U.S. Coast Guard, Commander,
Seventh Coast Guard District.
[FR Doc. 2020–22607 Filed 10–19–20; 8:45 am]
BILLING CODE 9110–04–P
DEPARTMENT OF COMMERCE
Patent and Trademark Office
37 CFR Part 42
[Docket No. PTO–C–2020–0055]
Request for Comments on Discretion
To Institute Trials Before the Patent
Trial and Appeal Board
Patent Trial and Appeal Board,
United States Patent and Trademark
Office, Department of Commerce.
ACTION: Request for comments.
AGENCY:
The United States Patent and
Trademark Office (Office or USPTO)
SUMMARY:
E:\FR\FM\20OCP1.SGM
20OCP1
Federal Register / Vol. 85, No. 203 / Tuesday, October 20, 2020 / Proposed Rules
seeks public comments on
considerations for instituting trials
before the Office under the Leahy-Smith
America Invents Act (AIA). The USPTO
is considering the codification of its
current policies and practices, or the
modification thereof, through
rulemaking and wishes to gather public
comments on the Office’s current
approach and on various other
approaches suggested to the Office by
stakeholders. To assist in gathering
public input, the USPTO is publishing
questions, and seeks focused public
comments, on appropriate
considerations for instituting AIA trials.
DATES: Comment date: Written
comments must be received on or before
November 19, 2020.
ADDRESSES: For reasons of government
efficiency, comments must be submitted
through the Federal eRulemaking Portal
at https://www.regulations.gov. To
submit comments via the portal, enter
docket number PTO–C–2020–0055 on
the home page and click ‘‘search.’’ The
site will provide a search results page
listing all documents associated with
this docket. Find a reference to this
Request for Comments and click on the
‘‘Comment Now!’’ icon, complete the
required fields, and enter or attach your
comments. Attachments to electronic
comments will be accepted in ADOBE®
portable document format or
MICROSOFT WORD® format. Because
comments will be made available for
public inspection, information that the
submitter does not desire to make
public, such as an address or phone
number, should not be included in the
comments.
Visit the Federal eRulemaking Portal
(https://www.regulations.gov) for
additional instructions on providing
comments via the portal. If electronic
submission of comments is not feasible
due to a lack of access to a computer
and/or the internet, please contact the
USPTO using the contact information
below for special instructions regarding
how to submit comments by mail or by
hand delivery, based on the public’s
ability to obtain access to USPTO
facilities at the time.
FOR FURTHER INFORMATION CONTACT:
Scott C. Weidenfeller, Vice Chief
Administrative Patent Judge, by
telephone at 571–272–9797.
SUPPLEMENTARY INFORMATION:
Background
Development of This Request for
Comments
On September 16, 2011, the AIA was
enacted into law (Pub. L. 112–29, 125
Stat. 284 (2011)), and in 2012, the Office
VerDate Sep<11>2014
16:48 Oct 19, 2020
Jkt 253001
implemented rules to govern Office trial
practice for AIA trials, including IPR,
PGR, CBM,1 and derivation proceedings
pursuant to 35 U.S.C. 135, 316, and 326
and AIA 18(d)(2). See Rules of Practice
for Trials Before the Patent Trial and
Appeal Board and Judicial Review of
Patent Trial and Appeal Board
Decisions, 77 FR 48612 (Aug. 14, 2012);
Changes to Implement Inter Partes
Review Proceedings, Post-Grant Review
Proceedings, and Transitional Program
for Covered Business Method Patents,
77 FR 48680 (Aug. 14, 2012);
Transitional Program for Covered
Business Method Patents—Definitions
of Covered Business Method Patent and
Technological Invention, 77 FR 48734
(Aug. 14, 2012). Additionally, the Office
published a Patent Trial Practice Guide
to advise the public on the general
framework of the rules and proceedings,
including the structure and times for
taking action in each of the new
proceedings. See Office Patent Trial
Practice Guide, 77 FR 48756 (Aug. 14,
2012). Since then, the Office has
designated more than 40 decisions in
such proceedings as precedential or
informative, and it has issued several
updates to the Trial Practice Guide that
were subsequently consolidated. See
Patent Trial and Appeal Board
Consolidated Trial Practice Guide (Nov.
2019) (Consolidated Trial Practice
Guide or CTPG), available at https://
www.uspto.gov/
TrialPracticeGuideConsolidated. In its
ongoing effort to achieve consistency
and fairness, the Office is considering
promulgating additional rules based on
this broad experience as it relates to
considerations for instituting AIA trials.
Discretion in Deciding Whether To
Institute AIA Trials
Director’s Discretionary Institution
Authority in General
By way of background, the Patent
Trial and Appeal Board (PTAB or
Board) institutes a trial on behalf of the
Director. 37 CFR 42.4(a); 35 U.S.C. 314.
In deciding whether to institute the
trial, the Board considers, at a
minimum, whether a petitioner has
satisfied the relevant statutory
institution standard. Even in cases
where a petitioner has satisfied the
institution standard, the statutes,
including 35 U.S.C. 314(a) and 324(a),
provide the Director with discretion to
deny a petition. See, e.g., 35 U.S.C.
1 Under Section 18 of the AIA, the transitional
program for post-grant review of covered business
method patents sunset on September 16, 2020. AIA
§ 18(a). Although the program has sunset, existing
CBM proceedings, based on petitions filed before
September 16, 2020, are still pending.
PO 00000
Frm 00013
Fmt 4702
Sfmt 4702
66503
314(a) (‘‘The Director may not authorize
an inter partes review to be instituted
unless . . .’’). The Supreme Court held
that ‘‘the agency’s decision to deny a
petition is a matter committed to the
Patent Office’s discretion,’’ and that
there is ‘‘no mandate to institute
review.’’ Cuozzo Speed Techs., LLC v.
Lee, 136 S. Ct. 2131, 2140 (2016).
The Director also is given broad
discretion under 35 U.S.C. 315(d) and
325(d) to determine the manner in
which ‘‘multiple proceedings’’ before
the Office involving the same patent
may proceed. Specifically, ‘‘the Director
may determine the manner in which the
. . . other proceeding or matter may
proceed, including providing for stay,
transfer, consolidation, or termination of
any such matter or proceeding.’’ Id.
Under 35 U.S.C. 316(a) and 326(a), the
Director shall prescribe regulations for
certain enumerated aspects of AIA
proceedings, and under 35 U.S.C.
2(b)(2)(A), the Director may establish
regulations that ‘‘shall govern the
conduct of proceedings in the Office.’’
Further, 35 U.S.C. 316(b) and 326(b)
require the Director to ‘‘consider the
effect of any such regulation [under this
section] on the economy, the integrity of
the patent system, the efficient
administration of the Office, and the
ability of the Office to timely complete
proceedings instituted under this
chapter.’’
Congress designed the AIA ‘‘to
establish a more efficient and
streamlined patent system that will
improve patent quality and limit
unnecessary and counterproductive
litigation costs.’’ H.R. Rep. No. 112–98,
pt. 1, at 40 (2011), 2011 U.S.C.C.A.N. 67,
69; see also S. Rep. No. 110–259, at 20
(2008). At the same time, Congress
instructed that ‘‘the changes made by
[the AIA] are not to be used as tools for
harassment or a means to prevent
market entry through repeated litigation
and administrative attacks on the
validity of a patent. Doing so would
frustrate the purpose of the section as
providing quick and cost effective
alternatives to litigation.’’ H.R. Rep. No.
112–98, at 48 (2011).
To achieve the appropriate balance
envisioned by Congress, the Office has
taken into account a variety of factors
when determining whether to institute a
proceeding. In so doing, the Office has
also taken into account the
considerations identified in 35 U.S.C.
316(b) and 326(b): The economy, the
integrity of the patent system, the
efficient administration of the Office,
and the ability of the Office to timely
complete instituted proceedings. The
Office has also worked to address the
emergence of repeated administrative
E:\FR\FM\20OCP1.SGM
20OCP1
66504
Federal Register / Vol. 85, No. 203 / Tuesday, October 20, 2020 / Proposed Rules
attacks on the patentability of the same
patent claims and the harassment of
patent owners.
The case-specific analysis the Office
has developed attempt to balance
Congress’s intent for AIA proceedings to
be ‘‘quick and cost effective alternatives
to litigation,’’ on the one hand, with
‘‘the importance of quiet title to patent
owners to ensure continued investment
resources,’’ on the other hand. H.R. Rep.
No. 112–98, pt. 1, at 48 (2011). For
example, the Office has set forth, in
various precedential PTAB decisions,
various factors used in its case-specific
analysis. See, e.g., General Plastic Co.,
Ltd. v. Canon Kabushiki Kaisha,
IPR2016–01357, 2017 WL 3917706, at
*7 (PTAB Sept. 6, 2017) (precedential)
(providing a nonexclusive list of factors
that the Board considers when
evaluating discretionary denial of
follow-on petitions, also known as
‘‘serial’’ petitions, under 35 U.S.C.
314(a)); Valve Corp. v. Elec. Scripting
Prods., Inc., IPR2019–00062, –00063,
–00084, 2019 WL 1490575 (PTAB Apr.
2, 2019) (precedential) (Valve I)
(explaining that the Board considers any
relationship between petitioners when
weighing the General Plastic factors);
Valve Corp. v. Elec. Scripting Prods.,
Inc., IPR2019–00064, –00065, –00085,
2019 WL 1965688 (PTAB May 1, 2019)
(Valve II) (applying the first General
Plastic factor to a petitioner that joined
a previously instituted IPR proceeding
and, therefore, is considered to have
previously filed a petition directed to
the same claims of the same patent);
Apple Inc. v. Fintiv, Inc., IPR2020–
00019, 2020 WL 2126495 (PTAB Mar.
20, 2020) (precedential) (summarizing
the factors the Office has considered
when a patent owner argues for
discretionary denial under NHK Spring
Co., Ltd. v. Intri-Plex Techs., Inc.,
IPR2018–00752, 2018 WL 4373643
(PTAB Sept. 12, 2018) (precedential)
due to an earlier trial date).
These same considerations are also
represented in various informative
decisions. See, e.g., Sand Revolution II,
LLC v. Continental Intermodal GroupTrucking LLC, 2020 WL 3273334 (PTAB
June 16, 2020) (informative) (applying
the factors set forth in the precedential
Fintiv decision to grant institution);
Apple Inc. v. Fintiv, Inc., IPR2020–
00019, 2020 WL 2486683 (PTAB May
13, 2020) (informative) (applying the
factors set forth in the precedential
Fintiv decision to deny institution);
Adaptics Ltd. v. Perfect Co., IPR2018–
01596, 2019 WL 1084284 (PTAB Mar. 6,
2019) (informative) (applying discretion
to deny a petition where the petition
lacks particularity in identifying the
asserted challenges that resulted in
VerDate Sep<11>2014
16:48 Oct 19, 2020
Jkt 253001
voluminous and excessive grounds);
Deeper, UAB v. Vexilar, Inc., IPR2018–
01310, 2019 WL 328753 (PTAB Jan. 24,
2019) (informative) (applying discretion
to deny a petition where the petitioner
demonstrates a reasonable likelihood of
prevailing only as to 2 claims out of 23
claims challenged and only as to 1 of 4
asserted grounds of unpatentability);
Chevron Oronite Co. v. Infineum USA
L.P., IPR2018–00923, 2018 WL 5862245
(PTAB Nov. 7, 2018) (informative)
(applying discretion to deny a petition
where the petitioner demonstrates a
reasonable likelihood of prevailing only
as to 2 claims out of 20 claims
challenged).
As the Office explained in the
Consolidated Trial Practice Guide,
consideration of this case-specific
analysis is ‘‘part of a balanced
assessment of all relevant circumstances
in the case, including the merits.’’ CTPG
at 58 (discussing consideration of the
merits as part of a balanced assessment
of the General Plastic factors); see also
Fintiv, 2020 WL 2126495, at *2–3, 6–7
(discussing consideration of the merits
in the context of discretionary denial).
Informed by similar considerations,
the Office has also provided guidance
on the number of petitions typically
required by a petitioner to challenge the
same patent at or about the same time.
See CTPG 59–61 (first introduced in
Trial Practice Guide Update (July 2019)
at 26–28, available at https://
www.uspto.gov/TrialPracticeGuide3
(requiring petitioners to rank multiple
petitions filed at the same time that seek
to challenge the same patent)). The
Board explained that, based on its prior
experience, ‘‘one petition should be
sufficient to challenge the claims of a
patent in most situations.’’ Id. at 59. In
some cases, depending on
circumstances, ‘‘two petitions by a
petitioner may be needed, although this
should be rare.’’ Id. The Board,
however, concluded that it is ‘‘unlikely
that circumstances will arise where
three or more petitions by a petitioner
with respect to a particular patent will
be appropriate.’’ Id.
The Office is now considering
promulgating rules based on the
framework of the guidance provided in
these decisions and in the Consolidated
Trial Practice Guide, or a modified
framework as appropriate, based on
public input and further analysis. These
considerations form the impetus for this
request for comments and the questions
presented below.
PO 00000
Frm 00014
Fmt 4702
Sfmt 4702
Discretion Under 35 U.S.C. 314(a) and
324(a)
Addressing Serial Petitions
In General Plastic, the Board
recognized the goals of the AIA and also
‘‘recognize[d] the potential for abuse of
the review process by repeated attacks
on patents.’’ 2017 WL 3917706, at *7
(citing H.R. Rep. No. 112–98, pt. 1, at 48
(2011)). To aid the Board’s assessment
of ‘‘the potential impacts on both the
efficiency of the IPR process and the
fundamental fairness of the process for
all parties,’’ General Plastic enumerated
a number of nonexclusive factors that
the Board will consider in a casespecific analysis for exercising
discretion on instituting an IPR,
especially as to ‘‘follow-on’’ or ‘‘serial’’
petitions challenging the same patent as
challenged previously in an IPR, PGR,
or CBM proceeding. Id. at *8. The
General Plastic nonexclusive factors
include: (1) Whether the same petitioner
previously filed a petition directed to
the same claims of the same patent; (2)
whether, at the time of filing of the first
petition, the petitioner knew of the prior
art asserted in the second petition or
should have known of it; (3) whether, at
the time of filing of the second petition,
the petitioner had already received a
patent owner’s preliminary response to
the first petition or received the Board’s
decision on whether to institute review
in the first petition; (4) the length of
time that elapsed between the time the
petitioner learned of the prior art
asserted in the second petition and the
filing of the second petition; (5) whether
the petitioner provides an adequate
explanation for the time elapsed
between the filings of multiple petitions
directed to the same claims of the same
patent; (6) the finite resources of the
Board; and (7) the requirement under 35
U.S.C. 316(a)(11) to issue a final
determination not later than one year
after the date on which the Director
notices institution of review. Id. at *7.
Since General Plastic, the Office has
explained that the application of the
first General Plastic factor is not limited
to instances where multiple petitions
are filed by the same petitioner. For
instance, in Valve I, the Board denied
institution when a party filed follow-on
petitions for IPR after the denial of an
earlier IPR request of the same claims
filed by the party’s co-defendant. Valve
I, 2019 WL 1490575, at *4–5. The Board
held that when different petitioners
challenge the same patent, the Board
considers the relationship, if any,
between those petitioners when
weighing the General Plastic factors. Id.
The Office also explained, in Valve II,
that the first General Plastic factor
E:\FR\FM\20OCP1.SGM
20OCP1
Federal Register / Vol. 85, No. 203 / Tuesday, October 20, 2020 / Proposed Rules
applies to a later petitioner when this
petitioner previously joined an
instituted IPR proceeding and, therefore,
was considered to have previously filed
a petition directed to the same claims of
the same patent. Valve II, 2019 WL
1965688, at *4–5. The relationships
between petitioners in follow-on
petition scenarios depend on the
circumstances of the follow-on petition
scenario.
Addressing Timely Completion of
Proceedings and Efficient
Administration of the Office
General Plastic also includes
additional factors that are not limited to
the follow-on petitions but are more
generally directed toward the timely
completion of proceedings and efficient
administration of the Office. Under
SAS, if the Board decides to institute
based on one claim, it must institute on
all claims and grounds set forth in the
petition. SAS, 138 S. Ct. at 1359–60;
Adidas AG v. Nike, Inc., 894 F.3d 1256,
1258 (Fed. Cir. 2018) (‘‘[e]qual treatment
of claims and grounds for institution
purposes has pervasive support in
SAS’’). As explained in the
Consolidated Trial Practice Guide,
however, the Board may decide not to
institute the petition if it determines
that the petition meets the standards for
institution in relation to fewer than all
the challenges presented, even when the
petition includes at least one claim
subject to a challenge that otherwise
meets the criteria for institution. CTPG
at 64 (discussing Deeper and Chevron).
Likewise, the Board may decide not to
institute where deficiencies in the
petition, such as a lack of particularity
in identifying the asserted challenges,
result in voluminous and excessive
grounds. See Adaptics, 2019 WL
1084284, at *7–10.
Addressing Parallel Petitions
As explained in the Consolidated
Trial Practice Guide in relation to
parallel petitions challenging the same
patent at or about the same time, in the
Board’s experience, one petition should
be sufficient for a petitioner to challenge
the claims of a patent in most situations.
CTPG at 59. The Office has explained
that ‘‘[t]wo or more petitions filed
against the same patent at or about the
same time (e.g., before the first
preliminary response by a patent owner)
may place a substantial and unnecessary
burden on the Board and the patent
owner and could raise fairness, timing,
and efficiency concerns.’’ Id. The Office
has also explained that ‘‘multiple
petitions by a petitioner are not
necessary in the vast majority of cases.’’
Id. (‘‘To date, a substantial majority of
VerDate Sep<11>2014
16:48 Oct 19, 2020
Jkt 253001
patents have been challenged with a
single petition.’’).
Nonetheless, the Office explained that
circumstances may exist in which more
than one petition may be necessary,
including, for example, when a patent
owner has asserted a large number of
claims in litigation or when there is a
dispute about priority date, thereby
requiring unpatentability challenges
under multiple prior art references. Id.
‘‘In such cases two petitions by a
petitioner may be needed, although this
should be rare.’’ Id. The Office also
explained that ‘‘based on prior
experience, the Board finds it unlikely
that circumstances will arise where
three or more petitions by a petitioner
with respect to a particular patent will
be appropriate.’’ Id. To aid the Board in
this case-specific analysis for
determining whether more than one
petition is necessary, the Office directed
the parties to address the issue in their
pre-institution filings. Id. at 59–60.
Addressing Proceedings in Other
Tribunals
The Consolidated Trial Practice Guide
explains that events in other
proceedings related to the same patent,
either at the Office, in U.S. district
courts or at the U.S. International Trade
Commission (ITC), may also impact the
institution decision. CTPG at 58. In a
prior precedential decision, for
example, the Board found that the
advanced state of a district court
proceeding was a factor weighing in
favor of not instituting under 35 U.S.C.
314(a), in addition to arguments under
35 U.S.C. 325(d). NHK, 2018 WL
4373643, at *7. Such advanced
proceedings in other tribunals have the
potential to undermine the intent that
AIA proceedings be quick and costeffective alternatives, and instead may
add costs, lengthen the proceedings, and
risk coordinate branches of the
Government having different outcomes
on similar facts.
Since designating NHK as
precedential, the Board has applied
nonexclusive factors that it considers in
a case-specific analysis when a patent
owner raises an argument for
discretionary denial based on a parallel
proceeding in another tribunal, such as
a U.S. district court. The Board recently
summarized these factors in Fintiv: (1)
Whether the court granted a stay or
evidence exists that one may be granted
if a proceeding is instituted; (2)
proximity of the court’s trial date to the
Board’s projected statutory deadline for
a final written decision; (3) investment
in the parallel proceeding by the court
and the parties; (4) overlap between the
issues raised in the petition and in the
PO 00000
Frm 00015
Fmt 4702
Sfmt 4702
66505
parallel proceeding; (5) whether the
petitioner and the defendant in the
parallel proceeding are the same party;
and (6) other circumstances that impact
the Board’s exercise of discretion,
including the merits. Fintiv, 2020 WL
2126495, at *2–3. The Board explained
that ‘‘[t]hese factors relate to whether
efficiency, fairness, and the merits
support the exercise of authority to deny
institution in view of an earlier trial
date in the parallel proceeding.’’ Id. at
*3.
Public Input
The Office already has received input
from stakeholders on the Office policies
discussed above and on use of the
Office’s discretion in institution of an
AIA trial. The most prevalent input that
the Office has received from
stakeholders is that the case-specific
analysis outlined in the foregoing
precedential opinions and the
Consolidated Trial Practice Guide
achieves the appropriate balance and
reduces gamesmanship. Among other
things, stakeholders have indicated that
the Office’s use of discretion as outlined
above helps to ensure that (a) AIA
proceedings do not create excessive
costs and uncertainty for the patent
owner and the system, while (b)
meritorious challenges by petitioners
can be maintained.
However, some stakeholders have
proposed that the Office adopt a brightline rule that it should use its discretion
to preclude claims from being subject to
more than one AIA proceeding,
regardless of the circumstances. In other
words, once a trial is instituted against
certain claims, this proposal would
preclude the Office from instituting
further AIA trials that include
challenges by any party to any of the
same claims if the patent owner opposes
institution.
Other stakeholders have proposed
that the Office should only permit more
than one AIA proceeding if the followon petitioner is unrelated to the prior
petitioner. A petitioner, a petitioner’s
real parties in interest, and privies of a
petitioner would be limited to filing a
single petition for a challenged claim,
regardless of the circumstances.
By contrast, the Office has received
input from some stakeholders proposing
that the Office adopt a bright-line
approach that there should be no limits
on the number of petitions that can be
filed or the number of AIA trials that
can be instituted against the claims of a
patent, so long as the petition complies
with statutory timing requirements, e.g.,
the one-year bar under 35 U.S.C. 315(b),
and meets the particular institution
E:\FR\FM\20OCP1.SGM
20OCP1
66506
Federal Register / Vol. 85, No. 203 / Tuesday, October 20, 2020 / Proposed Rules
threshold of showing that at least one
claim of the patent is unpatentable.
The Office has also received input
from stakeholders proposing that the
Office adopt a bright-line rule that
precludes institution of an AIA trial
against challenged claims if the patent
owner opposes institution and any of
the challenged claims are or have been
asserted against the petitioner, the
petitioner’s real party in interest, or a
privy of the petitioner in a district court
or ITC action that is unlikely to be
stayed.
By contrast, the Office also has
received input from other stakeholders
proposing that the Office adopt a brightline rule to eliminate any consideration
of the state of any district court or ITC
actions involving the challenged patent,
so long as the petition complies with
statutory timing requirements and meets
the particular institution threshold of
showing that at least one claim of the
patent is unpatentable.
In light of the various contrasting
views from some stakeholders, the
Office solicits further public input on
what should be considered as part of a
balanced assessment of the relevant
circumstances when exercising its
discretion to institute an AIA trial.
Issues for Comment
The USPTO seeks comments on
considerations for instituting AIA trials
as it relates to serial and parallel AIA
petitions, as well as proceedings in
other tribunals. The questions
enumerated below are a preliminary
guide to aid the USPTO in collecting
relevant information to assist in
modifications, if any, to its current
practices, and in the development of
any possible rulemaking on this subject.
The questions should not be taken as an
indication that the USPTO has taken a
position or is predisposed to any
particular views. The USPTO welcomes
comments from the public on any issues
believed to be relevant to these topics,
and is particularly interested in answers
to the following questions:
Serial Petitions
1. Should the Office promulgate a rule
with a case-specific analysis, such as
generally outlined in General Plastic,
Valve I, Valve II and their progeny, for
deciding whether to institute a petition
on claims that have previously been
challenged in another petition?
2. Alternatively, in deciding whether
to institute a petition, should the Office
(a) altogether disregard whether the
claims have previously been challenged
in another petition, or (b) altogether
decline to institute if the claims have
VerDate Sep<11>2014
16:48 Oct 19, 2020
Jkt 253001
previously been challenged in another
petition?
ENVIRONMENTAL PROTECTION
AGENCY
Parallel Petitions
40 CFR Part 721
3. Should the Office promulgate a rule
with a case-specific analysis, such as
generally outlined in the Consolidated
Trial Practice Guide, for deciding
whether to institute more than one
petition filed at or about the same time
on the same patent?
4. Alternatively, in deciding whether
to institute more than one petition filed
at or about the same time on the same
patent, should the Office (a) altogether
disregard the number of petitions filed,
or (b) altogether decline to institute on
more than one petition?
Proceedings in Other Tribunals
5. Should the Office promulgate a rule
with a case-specific analysis, such as
generally outlined in Fintiv and its
progeny, for deciding whether to
institute a petition on a patent that is or
has been subject to other proceedings in
a U.S. district court or the ITC?
6. Alternatively, in deciding whether
to institute a petition on a patent that is
or has been subject to other proceedings
in district court or the ITC, should the
Office (a) altogether disregard such
other proceedings, or (b) altogether
decline to institute if the patent that is
or has been subject to such other
proceedings, unless the district court or
the ITC has indicated that it will stay
the action?
Other Considerations
7. Whether or not the Office
promulgates rules on these issues, are
there any other modifications the Office
should make in its approach to serial
and parallel AIA petitions, proceedings
in other tribunals, or other use of
discretion in deciding whether to
institute an AIA trial?
Andrei Iancu,
Under Secretary of Commerce for Intellectual
Property and Director of the United States
Patent and Trademark Office.
[FR Doc. 2020–22946 Filed 10–19–20; 8:45 am]
BILLING CODE 3510–16–P
PO 00000
Frm 00016
Fmt 4702
Sfmt 4702
[EPA–HQ–OPPT–2020–0497; FRL–10015–
28]
RIN 2070–AB27
Significant New Use Rules on Certain
Chemical Substances (20–10.B)
Environmental Protection
Agency (EPA).
ACTION: Proposed rule.
AGENCY:
EPA is proposing significant
new use rules (SNURs) under the Toxic
Substances Control Act (TSCA) for
chemical substances which are the
subject of premanufacture notices
(PMNs). This action would require
persons to notify EPA at least 90 days
before commencing manufacture
(defined by statute to include import) or
processing of any of these chemical
substances for an activity that is
designated as a significant new use by
this proposed rule. This action would
further require that persons not
commence manufacture or processing
for the significant new use until they
have submitted a Significant New Use
Notice (SNUN), and EPA has conducted
a review of the notice, made an
appropriate determination on the notice,
and has taken any risk management
actions as are required as a result of that
determination.
DATES: Comments must be received on
or before November 19, 2020.
ADDRESSES: Submit your comments,
identified by docket identification (ID)
number EPA–HQ–OPPT–2020–0497,
using the Federal eRulemaking Portal at
https://www.regulations.gov. Follow the
online instructions for submitting
comments. Do not submit electronically
any information you consider to be
Confidential Business Information (CBI)
or other information whose disclosure is
restricted by statute.
Due to the public health emergency,
the EPA Docket Center (EPA/DC) and
Reading Room is closed to visitors with
limited exceptions. The staff continues
to provide remote customer service via
email, phone, and webform. For the
latest status information on EPA/DC
services and docket access, visit https://
www.epa.gov/dockets.
FOR FURTHER INFORMATION CONTACT:
For technical information contact:
William Wysong, Chemical Control
Division (7405M), Office of Pollution
Prevention and Toxics, Environmental
Protection Agency, 1200 Pennsylvania
Ave. NW, Washington, DC 20460–0001;
SUMMARY:
E:\FR\FM\20OCP1.SGM
20OCP1
Agencies
[Federal Register Volume 85, Number 203 (Tuesday, October 20, 2020)]
[Proposed Rules]
[Pages 66502-66506]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-22946]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Patent and Trademark Office
37 CFR Part 42
[Docket No. PTO-C-2020-0055]
Request for Comments on Discretion To Institute Trials Before the
Patent Trial and Appeal Board
AGENCY: Patent Trial and Appeal Board, United States Patent and
Trademark Office, Department of Commerce.
ACTION: Request for comments.
-----------------------------------------------------------------------
SUMMARY: The United States Patent and Trademark Office (Office or
USPTO)
[[Page 66503]]
seeks public comments on considerations for instituting trials before
the Office under the Leahy-Smith America Invents Act (AIA). The USPTO
is considering the codification of its current policies and practices,
or the modification thereof, through rulemaking and wishes to gather
public comments on the Office's current approach and on various other
approaches suggested to the Office by stakeholders. To assist in
gathering public input, the USPTO is publishing questions, and seeks
focused public comments, on appropriate considerations for instituting
AIA trials.
DATES: Comment date: Written comments must be received on or before
November 19, 2020.
ADDRESSES: For reasons of government efficiency, comments must be
submitted through the Federal eRulemaking Portal at https://www.regulations.gov. To submit comments via the portal, enter docket
number PTO-C-2020-0055 on the home page and click ``search.'' The site
will provide a search results page listing all documents associated
with this docket. Find a reference to this Request for Comments and
click on the ``Comment Now!'' icon, complete the required fields, and
enter or attach your comments. Attachments to electronic comments will
be accepted in ADOBE[supreg] portable document format or MICROSOFT
WORD[supreg] format. Because comments will be made available for public
inspection, information that the submitter does not desire to make
public, such as an address or phone number, should not be included in
the comments.
Visit the Federal eRulemaking Portal (https://www.regulations.gov)
for additional instructions on providing comments via the portal. If
electronic submission of comments is not feasible due to a lack of
access to a computer and/or the internet, please contact the USPTO
using the contact information below for special instructions regarding
how to submit comments by mail or by hand delivery, based on the
public's ability to obtain access to USPTO facilities at the time.
FOR FURTHER INFORMATION CONTACT: Scott C. Weidenfeller, Vice Chief
Administrative Patent Judge, by telephone at 571-272-9797.
SUPPLEMENTARY INFORMATION:
Background
Development of This Request for Comments
On September 16, 2011, the AIA was enacted into law (Pub. L. 112-
29, 125 Stat. 284 (2011)), and in 2012, the Office implemented rules to
govern Office trial practice for AIA trials, including IPR, PGR,
CBM,\1\ and derivation proceedings pursuant to 35 U.S.C. 135, 316, and
326 and AIA 18(d)(2). See Rules of Practice for Trials Before the
Patent Trial and Appeal Board and Judicial Review of Patent Trial and
Appeal Board Decisions, 77 FR 48612 (Aug. 14, 2012); Changes to
Implement Inter Partes Review Proceedings, Post-Grant Review
Proceedings, and Transitional Program for Covered Business Method
Patents, 77 FR 48680 (Aug. 14, 2012); Transitional Program for Covered
Business Method Patents--Definitions of Covered Business Method Patent
and Technological Invention, 77 FR 48734 (Aug. 14, 2012). Additionally,
the Office published a Patent Trial Practice Guide to advise the public
on the general framework of the rules and proceedings, including the
structure and times for taking action in each of the new proceedings.
See Office Patent Trial Practice Guide, 77 FR 48756 (Aug. 14, 2012).
Since then, the Office has designated more than 40 decisions in such
proceedings as precedential or informative, and it has issued several
updates to the Trial Practice Guide that were subsequently
consolidated. See Patent Trial and Appeal Board Consolidated Trial
Practice Guide (Nov. 2019) (Consolidated Trial Practice Guide or CTPG),
available at https://www.uspto.gov/TrialPracticeGuideConsolidated. In
its ongoing effort to achieve consistency and fairness, the Office is
considering promulgating additional rules based on this broad
experience as it relates to considerations for instituting AIA trials.
---------------------------------------------------------------------------
\1\ Under Section 18 of the AIA, the transitional program for
post-grant review of covered business method patents sunset on
September 16, 2020. AIA Sec. 18(a). Although the program has
sunset, existing CBM proceedings, based on petitions filed before
September 16, 2020, are still pending.
---------------------------------------------------------------------------
Discretion in Deciding Whether To Institute AIA Trials
Director's Discretionary Institution Authority in General
By way of background, the Patent Trial and Appeal Board (PTAB or
Board) institutes a trial on behalf of the Director. 37 CFR 42.4(a); 35
U.S.C. 314. In deciding whether to institute the trial, the Board
considers, at a minimum, whether a petitioner has satisfied the
relevant statutory institution standard. Even in cases where a
petitioner has satisfied the institution standard, the statutes,
including 35 U.S.C. 314(a) and 324(a), provide the Director with
discretion to deny a petition. See, e.g., 35 U.S.C. 314(a) (``The
Director may not authorize an inter partes review to be instituted
unless . . .''). The Supreme Court held that ``the agency's decision to
deny a petition is a matter committed to the Patent Office's
discretion,'' and that there is ``no mandate to institute review.''
Cuozzo Speed Techs., LLC v. Lee, 136 S. Ct. 2131, 2140 (2016).
The Director also is given broad discretion under 35 U.S.C. 315(d)
and 325(d) to determine the manner in which ``multiple proceedings''
before the Office involving the same patent may proceed. Specifically,
``the Director may determine the manner in which the . . . other
proceeding or matter may proceed, including providing for stay,
transfer, consolidation, or termination of any such matter or
proceeding.'' Id.
Under 35 U.S.C. 316(a) and 326(a), the Director shall prescribe
regulations for certain enumerated aspects of AIA proceedings, and
under 35 U.S.C. 2(b)(2)(A), the Director may establish regulations that
``shall govern the conduct of proceedings in the Office.'' Further, 35
U.S.C. 316(b) and 326(b) require the Director to ``consider the effect
of any such regulation [under this section] on the economy, the
integrity of the patent system, the efficient administration of the
Office, and the ability of the Office to timely complete proceedings
instituted under this chapter.''
Congress designed the AIA ``to establish a more efficient and
streamlined patent system that will improve patent quality and limit
unnecessary and counterproductive litigation costs.'' H.R. Rep. No.
112-98, pt. 1, at 40 (2011), 2011 U.S.C.C.A.N. 67, 69; see also S. Rep.
No. 110-259, at 20 (2008). At the same time, Congress instructed that
``the changes made by [the AIA] are not to be used as tools for
harassment or a means to prevent market entry through repeated
litigation and administrative attacks on the validity of a patent.
Doing so would frustrate the purpose of the section as providing quick
and cost effective alternatives to litigation.'' H.R. Rep. No. 112-98,
at 48 (2011).
To achieve the appropriate balance envisioned by Congress, the
Office has taken into account a variety of factors when determining
whether to institute a proceeding. In so doing, the Office has also
taken into account the considerations identified in 35 U.S.C. 316(b)
and 326(b): The economy, the integrity of the patent system, the
efficient administration of the Office, and the ability of the Office
to timely complete instituted proceedings. The Office has also worked
to address the emergence of repeated administrative
[[Page 66504]]
attacks on the patentability of the same patent claims and the
harassment of patent owners.
The case-specific analysis the Office has developed attempt to
balance Congress's intent for AIA proceedings to be ``quick and cost
effective alternatives to litigation,'' on the one hand, with ``the
importance of quiet title to patent owners to ensure continued
investment resources,'' on the other hand. H.R. Rep. No. 112-98, pt. 1,
at 48 (2011). For example, the Office has set forth, in various
precedential PTAB decisions, various factors used in its case-specific
analysis. See, e.g., General Plastic Co., Ltd. v. Canon Kabushiki
Kaisha, IPR2016-01357, 2017 WL 3917706, at *7 (PTAB Sept. 6, 2017)
(precedential) (providing a nonexclusive list of factors that the Board
considers when evaluating discretionary denial of follow-on petitions,
also known as ``serial'' petitions, under 35 U.S.C. 314(a)); Valve
Corp. v. Elec. Scripting Prods., Inc., IPR2019-00062, -00063, -00084,
2019 WL 1490575 (PTAB Apr. 2, 2019) (precedential) (Valve I)
(explaining that the Board considers any relationship between
petitioners when weighing the General Plastic factors); Valve Corp. v.
Elec. Scripting Prods., Inc., IPR2019-00064, -00065, -00085, 2019 WL
1965688 (PTAB May 1, 2019) (Valve II) (applying the first General
Plastic factor to a petitioner that joined a previously instituted IPR
proceeding and, therefore, is considered to have previously filed a
petition directed to the same claims of the same patent); Apple Inc. v.
Fintiv, Inc., IPR2020-00019, 2020 WL 2126495 (PTAB Mar. 20, 2020)
(precedential) (summarizing the factors the Office has considered when
a patent owner argues for discretionary denial under NHK Spring Co.,
Ltd. v. Intri-Plex Techs., Inc., IPR2018-00752, 2018 WL 4373643 (PTAB
Sept. 12, 2018) (precedential) due to an earlier trial date).
These same considerations are also represented in various
informative decisions. See, e.g., Sand Revolution II, LLC v.
Continental Intermodal Group-Trucking LLC, 2020 WL 3273334 (PTAB June
16, 2020) (informative) (applying the factors set forth in the
precedential Fintiv decision to grant institution); Apple Inc. v.
Fintiv, Inc., IPR2020-00019, 2020 WL 2486683 (PTAB May 13, 2020)
(informative) (applying the factors set forth in the precedential
Fintiv decision to deny institution); Adaptics Ltd. v. Perfect Co.,
IPR2018-01596, 2019 WL 1084284 (PTAB Mar. 6, 2019) (informative)
(applying discretion to deny a petition where the petition lacks
particularity in identifying the asserted challenges that resulted in
voluminous and excessive grounds); Deeper, UAB v. Vexilar, Inc.,
IPR2018-01310, 2019 WL 328753 (PTAB Jan. 24, 2019) (informative)
(applying discretion to deny a petition where the petitioner
demonstrates a reasonable likelihood of prevailing only as to 2 claims
out of 23 claims challenged and only as to 1 of 4 asserted grounds of
unpatentability); Chevron Oronite Co. v. Infineum USA L.P., IPR2018-
00923, 2018 WL 5862245 (PTAB Nov. 7, 2018) (informative) (applying
discretion to deny a petition where the petitioner demonstrates a
reasonable likelihood of prevailing only as to 2 claims out of 20
claims challenged).
As the Office explained in the Consolidated Trial Practice Guide,
consideration of this case-specific analysis is ``part of a balanced
assessment of all relevant circumstances in the case, including the
merits.'' CTPG at 58 (discussing consideration of the merits as part of
a balanced assessment of the General Plastic factors); see also Fintiv,
2020 WL 2126495, at *2-3, 6-7 (discussing consideration of the merits
in the context of discretionary denial).
Informed by similar considerations, the Office has also provided
guidance on the number of petitions typically required by a petitioner
to challenge the same patent at or about the same time. See CTPG 59-61
(first introduced in Trial Practice Guide Update (July 2019) at 26-28,
available at https://www.uspto.gov/TrialPracticeGuide3 (requiring
petitioners to rank multiple petitions filed at the same time that seek
to challenge the same patent)). The Board explained that, based on its
prior experience, ``one petition should be sufficient to challenge the
claims of a patent in most situations.'' Id. at 59. In some cases,
depending on circumstances, ``two petitions by a petitioner may be
needed, although this should be rare.'' Id. The Board, however,
concluded that it is ``unlikely that circumstances will arise where
three or more petitions by a petitioner with respect to a particular
patent will be appropriate.'' Id.
The Office is now considering promulgating rules based on the
framework of the guidance provided in these decisions and in the
Consolidated Trial Practice Guide, or a modified framework as
appropriate, based on public input and further analysis. These
considerations form the impetus for this request for comments and the
questions presented below.
Discretion Under 35 U.S.C. 314(a) and 324(a)
Addressing Serial Petitions
In General Plastic, the Board recognized the goals of the AIA and
also ``recognize[d] the potential for abuse of the review process by
repeated attacks on patents.'' 2017 WL 3917706, at *7 (citing H.R. Rep.
No. 112-98, pt. 1, at 48 (2011)). To aid the Board's assessment of
``the potential impacts on both the efficiency of the IPR process and
the fundamental fairness of the process for all parties,'' General
Plastic enumerated a number of nonexclusive factors that the Board will
consider in a case-specific analysis for exercising discretion on
instituting an IPR, especially as to ``follow-on'' or ``serial''
petitions challenging the same patent as challenged previously in an
IPR, PGR, or CBM proceeding. Id. at *8. The General Plastic
nonexclusive factors include: (1) Whether the same petitioner
previously filed a petition directed to the same claims of the same
patent; (2) whether, at the time of filing of the first petition, the
petitioner knew of the prior art asserted in the second petition or
should have known of it; (3) whether, at the time of filing of the
second petition, the petitioner had already received a patent owner's
preliminary response to the first petition or received the Board's
decision on whether to institute review in the first petition; (4) the
length of time that elapsed between the time the petitioner learned of
the prior art asserted in the second petition and the filing of the
second petition; (5) whether the petitioner provides an adequate
explanation for the time elapsed between the filings of multiple
petitions directed to the same claims of the same patent; (6) the
finite resources of the Board; and (7) the requirement under 35 U.S.C.
316(a)(11) to issue a final determination not later than one year after
the date on which the Director notices institution of review. Id. at
*7.
Since General Plastic, the Office has explained that the
application of the first General Plastic factor is not limited to
instances where multiple petitions are filed by the same petitioner.
For instance, in Valve I, the Board denied institution when a party
filed follow-on petitions for IPR after the denial of an earlier IPR
request of the same claims filed by the party's co-defendant. Valve I,
2019 WL 1490575, at *4-5. The Board held that when different
petitioners challenge the same patent, the Board considers the
relationship, if any, between those petitioners when weighing the
General Plastic factors. Id. The Office also explained, in Valve II,
that the first General Plastic factor
[[Page 66505]]
applies to a later petitioner when this petitioner previously joined an
instituted IPR proceeding and, therefore, was considered to have
previously filed a petition directed to the same claims of the same
patent. Valve II, 2019 WL 1965688, at *4-5. The relationships between
petitioners in follow-on petition scenarios depend on the circumstances
of the follow-on petition scenario.
Addressing Timely Completion of Proceedings and Efficient
Administration of the Office
General Plastic also includes additional factors that are not
limited to the follow-on petitions but are more generally directed
toward the timely completion of proceedings and efficient
administration of the Office. Under SAS, if the Board decides to
institute based on one claim, it must institute on all claims and
grounds set forth in the petition. SAS, 138 S. Ct. at 1359-60; Adidas
AG v. Nike, Inc., 894 F.3d 1256, 1258 (Fed. Cir. 2018) (``[e]qual
treatment of claims and grounds for institution purposes has pervasive
support in SAS''). As explained in the Consolidated Trial Practice
Guide, however, the Board may decide not to institute the petition if
it determines that the petition meets the standards for institution in
relation to fewer than all the challenges presented, even when the
petition includes at least one claim subject to a challenge that
otherwise meets the criteria for institution. CTPG at 64 (discussing
Deeper and Chevron). Likewise, the Board may decide not to institute
where deficiencies in the petition, such as a lack of particularity in
identifying the asserted challenges, result in voluminous and excessive
grounds. See Adaptics, 2019 WL 1084284, at *7-10.
Addressing Parallel Petitions
As explained in the Consolidated Trial Practice Guide in relation
to parallel petitions challenging the same patent at or about the same
time, in the Board's experience, one petition should be sufficient for
a petitioner to challenge the claims of a patent in most situations.
CTPG at 59. The Office has explained that ``[t]wo or more petitions
filed against the same patent at or about the same time (e.g., before
the first preliminary response by a patent owner) may place a
substantial and unnecessary burden on the Board and the patent owner
and could raise fairness, timing, and efficiency concerns.'' Id. The
Office has also explained that ``multiple petitions by a petitioner are
not necessary in the vast majority of cases.'' Id. (``To date, a
substantial majority of patents have been challenged with a single
petition.'').
Nonetheless, the Office explained that circumstances may exist in
which more than one petition may be necessary, including, for example,
when a patent owner has asserted a large number of claims in litigation
or when there is a dispute about priority date, thereby requiring
unpatentability challenges under multiple prior art references. Id.
``In such cases two petitions by a petitioner may be needed, although
this should be rare.'' Id. The Office also explained that ``based on
prior experience, the Board finds it unlikely that circumstances will
arise where three or more petitions by a petitioner with respect to a
particular patent will be appropriate.'' Id. To aid the Board in this
case-specific analysis for determining whether more than one petition
is necessary, the Office directed the parties to address the issue in
their pre-institution filings. Id. at 59-60.
Addressing Proceedings in Other Tribunals
The Consolidated Trial Practice Guide explains that events in other
proceedings related to the same patent, either at the Office, in U.S.
district courts or at the U.S. International Trade Commission (ITC),
may also impact the institution decision. CTPG at 58. In a prior
precedential decision, for example, the Board found that the advanced
state of a district court proceeding was a factor weighing in favor of
not instituting under 35 U.S.C. 314(a), in addition to arguments under
35 U.S.C. 325(d). NHK, 2018 WL 4373643, at *7. Such advanced
proceedings in other tribunals have the potential to undermine the
intent that AIA proceedings be quick and cost-effective alternatives,
and instead may add costs, lengthen the proceedings, and risk
coordinate branches of the Government having different outcomes on
similar facts.
Since designating NHK as precedential, the Board has applied
nonexclusive factors that it considers in a case-specific analysis when
a patent owner raises an argument for discretionary denial based on a
parallel proceeding in another tribunal, such as a U.S. district court.
The Board recently summarized these factors in Fintiv: (1) Whether the
court granted a stay or evidence exists that one may be granted if a
proceeding is instituted; (2) proximity of the court's trial date to
the Board's projected statutory deadline for a final written decision;
(3) investment in the parallel proceeding by the court and the parties;
(4) overlap between the issues raised in the petition and in the
parallel proceeding; (5) whether the petitioner and the defendant in
the parallel proceeding are the same party; and (6) other circumstances
that impact the Board's exercise of discretion, including the merits.
Fintiv, 2020 WL 2126495, at *2-3. The Board explained that ``[t]hese
factors relate to whether efficiency, fairness, and the merits support
the exercise of authority to deny institution in view of an earlier
trial date in the parallel proceeding.'' Id. at *3.
Public Input
The Office already has received input from stakeholders on the
Office policies discussed above and on use of the Office's discretion
in institution of an AIA trial. The most prevalent input that the
Office has received from stakeholders is that the case-specific
analysis outlined in the foregoing precedential opinions and the
Consolidated Trial Practice Guide achieves the appropriate balance and
reduces gamesmanship. Among other things, stakeholders have indicated
that the Office's use of discretion as outlined above helps to ensure
that (a) AIA proceedings do not create excessive costs and uncertainty
for the patent owner and the system, while (b) meritorious challenges
by petitioners can be maintained.
However, some stakeholders have proposed that the Office adopt a
bright-line rule that it should use its discretion to preclude claims
from being subject to more than one AIA proceeding, regardless of the
circumstances. In other words, once a trial is instituted against
certain claims, this proposal would preclude the Office from
instituting further AIA trials that include challenges by any party to
any of the same claims if the patent owner opposes institution.
Other stakeholders have proposed that the Office should only permit
more than one AIA proceeding if the follow-on petitioner is unrelated
to the prior petitioner. A petitioner, a petitioner's real parties in
interest, and privies of a petitioner would be limited to filing a
single petition for a challenged claim, regardless of the
circumstances.
By contrast, the Office has received input from some stakeholders
proposing that the Office adopt a bright-line approach that there
should be no limits on the number of petitions that can be filed or the
number of AIA trials that can be instituted against the claims of a
patent, so long as the petition complies with statutory timing
requirements, e.g., the one-year bar under 35 U.S.C. 315(b), and meets
the particular institution
[[Page 66506]]
threshold of showing that at least one claim of the patent is
unpatentable.
The Office has also received input from stakeholders proposing that
the Office adopt a bright-line rule that precludes institution of an
AIA trial against challenged claims if the patent owner opposes
institution and any of the challenged claims are or have been asserted
against the petitioner, the petitioner's real party in interest, or a
privy of the petitioner in a district court or ITC action that is
unlikely to be stayed.
By contrast, the Office also has received input from other
stakeholders proposing that the Office adopt a bright-line rule to
eliminate any consideration of the state of any district court or ITC
actions involving the challenged patent, so long as the petition
complies with statutory timing requirements and meets the particular
institution threshold of showing that at least one claim of the patent
is unpatentable.
In light of the various contrasting views from some stakeholders,
the Office solicits further public input on what should be considered
as part of a balanced assessment of the relevant circumstances when
exercising its discretion to institute an AIA trial.
Issues for Comment
The USPTO seeks comments on considerations for instituting AIA
trials as it relates to serial and parallel AIA petitions, as well as
proceedings in other tribunals. The questions enumerated below are a
preliminary guide to aid the USPTO in collecting relevant information
to assist in modifications, if any, to its current practices, and in
the development of any possible rulemaking on this subject. The
questions should not be taken as an indication that the USPTO has taken
a position or is predisposed to any particular views. The USPTO
welcomes comments from the public on any issues believed to be relevant
to these topics, and is particularly interested in answers to the
following questions:
Serial Petitions
1. Should the Office promulgate a rule with a case-specific
analysis, such as generally outlined in General Plastic, Valve I, Valve
II and their progeny, for deciding whether to institute a petition on
claims that have previously been challenged in another petition?
2. Alternatively, in deciding whether to institute a petition,
should the Office (a) altogether disregard whether the claims have
previously been challenged in another petition, or (b) altogether
decline to institute if the claims have previously been challenged in
another petition?
Parallel Petitions
3. Should the Office promulgate a rule with a case-specific
analysis, such as generally outlined in the Consolidated Trial Practice
Guide, for deciding whether to institute more than one petition filed
at or about the same time on the same patent?
4. Alternatively, in deciding whether to institute more than one
petition filed at or about the same time on the same patent, should the
Office (a) altogether disregard the number of petitions filed, or (b)
altogether decline to institute on more than one petition?
Proceedings in Other Tribunals
5. Should the Office promulgate a rule with a case-specific
analysis, such as generally outlined in Fintiv and its progeny, for
deciding whether to institute a petition on a patent that is or has
been subject to other proceedings in a U.S. district court or the ITC?
6. Alternatively, in deciding whether to institute a petition on a
patent that is or has been subject to other proceedings in district
court or the ITC, should the Office (a) altogether disregard such other
proceedings, or (b) altogether decline to institute if the patent that
is or has been subject to such other proceedings, unless the district
court or the ITC has indicated that it will stay the action?
Other Considerations
7. Whether or not the Office promulgates rules on these issues, are
there any other modifications the Office should make in its approach to
serial and parallel AIA petitions, proceedings in other tribunals, or
other use of discretion in deciding whether to institute an AIA trial?
Andrei Iancu,
Under Secretary of Commerce for Intellectual Property and Director of
the United States Patent and Trademark Office.
[FR Doc. 2020-22946 Filed 10-19-20; 8:45 am]
BILLING CODE 3510-16-P